Compare STAG & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STAG | GKOS |
|---|---|---|
| Founded | 2010 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3B | 6.0B |
| IPO Year | 2010 | 2015 |
| Metric | STAG | GKOS |
|---|---|---|
| Price | $39.60 | $119.43 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 12 |
| Target Price | $39.56 | ★ $126.92 |
| AVG Volume (30 Days) | ★ 989.9K | 551.7K |
| Earning Date | 04-28-2026 | 04-29-2026 |
| Dividend Yield | ★ 3.93% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $845,184,000.00 | $507,442,000.00 |
| Revenue This Year | $8.59 | $23.32 |
| Revenue Next Year | $9.28 | $27.43 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 10.14 | ★ 32.33 |
| 52 Week Low | $31.79 | $73.16 |
| 52 Week High | $39.99 | $130.23 |
| Indicator | STAG | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 61.46 | 54.53 |
| Support Level | $36.80 | $104.72 |
| Resistance Level | $39.79 | $123.09 |
| Average True Range (ATR) | 0.63 | 3.95 |
| MACD | 0.13 | -0.18 |
| Stochastic Oscillator | 82.90 | 35.41 |
Stag Industrial Inc is a REIT focused on the acquisition, ownership, development, and operation of industrial properties throughout the United States. Its platform is designed to (i) identify properties for acquisition that offer attractive returns across CBRE-EA Tier 1 industrial real estate markets, industries, and tenants, (ii) provide growth through the ownership of high-quality assets, property management and pursuit of acquisitions in an attractive opportunity set, and (iii) capitalize its business appropriately given the characteristics of its assets. The majority of its portfolio is single-tenant industrial properties throughout the United States. The company derives the majority of its rental revenue from its facilities located in Midwestern and Eastern U.S. cities.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.